The thrombospondin-1 receptor CD36 is an important mediator of ovarian angiogenesis and folliculogenesis

Reproductive Biology and Endocrinology

Jim Petrik¹  Michelle Ross¹  Kata Osz¹ 

[1] Department of Biomedical Sciences, University of Guelph, Guelph, ON N1G 2W1, Canada

关键词: Angiogenesis;    Folliculogenesis;    Thrombospondin;    CD36;    Ovary;   

Others  :  804539
DOI  :  10.1186/1477-7827-12-21

 received in 2013-08-30, accepted in 2014-02-22,  发布年份 2014

【 摘 要 】

Background

Ovarian angiogenesis is a complex process that is regulated by a balance between pro- and anti-angiogenic factors. Physiological processes within the ovary, such as folliculogenesis, ovulation, and luteal formation are dependent upon adequate vascularization and anything that disrupts normal angiogenic processes may result in ovarian dysfunction, and possibly infertility. The objective of this study was to evaluate the role of the thrombospondin-1 (TSP-1) receptor CD36 in mediating ovarian angiogenesis and regulating ovarian function.

Methods

The role of CD36 was evaluated in granulosa cells in vitro and ovarian morphology and protein expression were determined in wild type and CD36 null mice.

Results

In vitro, CD36 inhibition increased granulosa cell proliferation and decreased apoptosis. Granulosa cells in which CD36 was knocked down also exhibited an increase in expression of survival and angiogenic proteins. Ovaries from CD36 null mice were hypervascularized, with increased expression of pro-angiogenic vascular endothelial growth factor (VEGF) and its receptor VEGFR-2. Ovaries from CD36 null mice contained an increase in the numbers of pre-ovulatory follicles and decreased numbers of corpora lutea. CD36 null mice also had fewer number of offspring compared to wild type controls.

Conclusions

The results from this study demonstrate that CD36 is integral to the regulation of ovarian angiogenesis by TSP-1 and the expression of these family members may be useful in the control of ovarian vascular disorders.

【 授权许可】

   
2014 Osz et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Greenaway J, Connor K, Pedersen HG, Coomber BL, LaMarre J, Petrik J: Vascular endothelial growth factor and its receptor, Flk-1/KDR, are cytoprotective in the extravascular compartment of the ovarian follicle. Endocrinology 2004, 145:2896-2905.
• [2]Lawler J: The functions of thrombospondin-1 and-2. Curr Opin Cell Biol 2000, 12:634-640.
• [3]Lawler J: Thrombospondin-1 as an endogenous inhibitor of angiogenesis and tumor growth. J Cell Mol Med 2002, 6:1-12.
• [4]Adams JC, Lawler J: The thrombospondins. Int J Biochem Cell B 2004, 36:961-968.
• [5]Adams JC, Lawler J: The thrombospondins. Cold Spring Harbor perspectives in biology 2011, 3:a009712.
• [6]Silverstein RL: The face of TSR revealed: an extracellular signaling domain is exposed. J Cell Biol 2002, 159:203-206.
• [7]Lawler J, Detmar M: Tumor progression: the effects of thrombospondin-1 and −2. Int J Biochem Cell B 2004, 36:1038-1045.
• [8]Ren B, Yee KO, Lawler J, Khosravi-Far R: Regulation of tumor angiogenesis by thrombospondin-1. Biochim Biophys Acta 2006, 1765:178-188.
• [9]Kulapaditharom B, Boonkitticharoen V, Sritara C: Plasma vascular endothelial growth factor dysregulation in defining aggressiveness of head and neck squamous cell carcinoma. J Oncol 2012, 2012:687934.
• [10]Koukourakis MI, Limberis V, Tentes I, Kontomanolis E, Kortsaris A, Sivridis E, Giatromanolaki A: Serum VEGF levels and tissue activation of VEGFR2/KDR receptors in patients with breast and gynecologic cancer. Cytokine 2011, 53:370-375.
• [11]Seow KM, Tsai YL, Hwang JL, Hsu WY, Ho LT, Juan CC: Omental adipose tissue overexpression of fatty acid transporter CD36 and decreased expression of hormone-sensitive lipase in insulin-resistant women with polycystic ovary syndrome. Hum Reprod 1982–1988, 2009:24.
• [12]Zhou J, Febbraio M, Wada T, Zhai Y, Kuruba R, He J, Lee JH, Khadem S, Ren S, Li S, Silverstein RL, Xie W: Hepatic fatty acid transporter Cd36 is a common target of LXR, PXR, and PPARgamma in promoting steatosis. Gastroenterology 2008, 134:556-567.
• [13]Silverstein RL, Febbraio M: CD36, a scavenger receptor involved in immunity, metabolism, angiogenesis, and behavior. Sci Signal 2009, 2:re3.
• [14]Febbraio M, Hajjar DP, Silverstein RL: CD36: a class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism. J Clin Invest 2001, 108:785-791.
• [15]Greenaway J, Gentry PA, Feige JJ, LaMarre J, Petrik JJ: Thrombospondin and vascular endothelial growth factor are cyclically expressed in an inverse pattern during bovine ovarian follicle development. Biol Reprod 2005, 72:1071-1078.
• [16]Petrik JJ, Gentry PA, Feige JJ, LaMarre J: Expression and localization of thrombospondin-1 and −2 and their cell-surface receptor, CD36, during rat follicular development and formation of the corpus luteum. Biol Reprod 2002, 67:1522-1531.
• [17]Hale JS, Li M, Sinyuk M, Jahnen-Dechent W, Lathia JD, Silverstein RL: Context dependent role of the CD36–thrombospondin–histidine-rich glycoprotein axis in tumor angiogenesis and growth. PloS One 2012, 7:e40033.
• [18]Silverstein RL, Febbraio M: CD36-TSP-HRGP interactions in the regulation of angiogenesis. Curr Pharm Design 2007, 13:3559-3567.
• [19]Rege TA, Stewart J Jr, Dranka B, Benveniste EN, Silverstein RL, Gladson CL: Thrombospondin-1-induced apoptosis of brain microvascular endothelial cells can be mediated by TNF-R1. J Cell Physiol 2009, 218:94-103.
• [20]Isenberg JS, Martin-Manso G, Maxhimer JB, Roberts DD: Regulation of nitric oxide signalling by thrombospondin 1: implications for anti-angiogenic therapies. Nat Rev Canc 2009, 9:182-194.
• [21]Jimenez B, Volpert OV, Crawford SE, Febbraio M, Silverstein RL, Bouck N: Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1. Nat Med 2000, 6:41-48.
• [22]Greenaway J, Lawler J, Moorehead R, Bornstein P, Lamarre J, Petrik J: Thrombospondin-1 inhibits VEGF levels in the ovary directly by binding and internalization via the low density lipoprotein receptor-related protein-1 (LRP-1). J Cell Physiol 2007, 210:807-818.
• [23]Garside SA, Harlow CR, Hillier SG, Fraser HM, Thomas FH: Thrombospondin-1 inhibits angiogenesis and promotes follicular atresia in a novel in vitro angiogenesis assay. Endocrinology 2010, 151:1280-1289.
• [24]Garside SA, Henkin J, Morris KD, Norvell SM, Thomas FH, Fraser HM: A thrombospondin-mimetic peptide, ABT-898, suppresses angiogenesis and promotes follicular atresia in pre- and early-antral follicles in vivo. Endocrinology 2010, 151:5905-5915.
• [25]Greenaway J, Henkin J, Lawler J, Moorehead R, Petrik J: ABT-510 induces tumor cell apoptosis and inhibits ovarian tumor growth in an orthotopic, syngeneic model of epithelial ovarian cancer. Mol Cancer Ther 2009, 8:64-74.
• [26]Stein LS, Stoica G, Tilley R, Burghardt RC: Rat ovarian granulosa cell culture: a model system for the study of cell-cell communication during multistep transformation. Cancer Res 1991, 51:696-706.
• [27]Robker RL, Akison LK, Bennett BD, Thrupp PN, Chura LR, Russell DL, Lane M, Norman RJ: Obese women exhibit differences in ovarian metabolites, hormones, and gene expression compared with moderate-weight women. J Clin Endocr Metab 2009, 94:1533-1540.
• [28]Serke H, Bausenwein J, Hirrlinger J, Nowicki M, Vilser C, Jogschies P, Hmeidan FA, Blumenauer V, Spanel-Borowski K: Granulosa cell subtypes vary in response to oxidized low-density lipoprotein as regards specific lipoprotein receptors and antioxidant enzyme activity. J Clin Endocr Metab 2010, 95:3480-3490.
• [29]Zhang X, Kazerounian S, Duquette M, Perruzzi C, Nagy JA, Dvorak HF, Parangi S, Lawler J: Thrombospondin-1 modulates vascular endothelial growth factor activity at the receptor level. FASEB J 2009, 23:3368-3376.
• [30]Primo L, Ferrandi C, Roca C, Marchio S, di Blasio L, Alessio M, Bussolino F: Identification of CD36 molecular features required for its in vitro angiostatic activity. FASEB J 2005, 19:1713-1715.
• [31]Goto M, Iwase A, Ando H, Kurotsuchi S, Harata T, Kikkawa F: PTEN and Akt expression during growth of human ovarian follicles. J Assist Reprod Gen 2007, 24:541-546.
• [32]Zhang P, Chao H, Sun X, Li L, Shi Q, Shen W: Murine folliculogenesis in vitro is stage-specifically regulated by insulin via the Akt signaling pathway. Histochem Cell Biol 2010, 134:75-82.
• [33]Sobinoff AP, Nixon B, Roman SD, McLaughlin EA: Staying alive: PI3K pathway promotes primordial follicle activation and survival in response to 3MC-induced ovotoxicity. Toxicol Sci 2012, 128:258-271.
• [34]Craig J, Orisaka M, Wang H, Orisaka S, Thompson W, Zhu C, Kotsuji F, Tsang BK: Gonadotropin and intra-ovarian signals regulating follicle development and atresia: the delicate balance between life and death. Frontiers Biosci 2007, 12:3628-3639.
• [35]Parborell F, Abramovich D, Irusta G, Tesone M: Angiopoietin 1 reduces rat follicular atresia mediated by apoptosis through the PI3K/Akt pathway. Mol Cell Endocrinol 2011, 343:79-87.
• [36]Thomas FH, Wilson H, Silvestri A, Fraser HM: Thrombospondin-1 expression is increased during follicular atresia in the primate ovary. Endocrinology 2008, 149:185-192.
• [37]Galvao A, Henriques S, Pestka D, Lukasik K, Skarzynski D, Mateus LM, Ferreira-Dias GM: Equine luteal function regulation may depend on the interaction between cytokines and vascular endothelial growth factor: an in vitro study. Biol Reprod 2012, 86:187.
• [38]Mwaikambo BR, Yang C, Ong H, Chemtob S, Hardy P: Emerging roles for the CD36 scavenger receptor as a potential therapeutic target for corneal neovascularization. Endoc Metab Immune Disord Drug Targets 2008, 8:255-272.
• [39]Kaur B, Cork SM, Sandberg EM, Devi NS, Zhang Z, Klenotic PA, Febbraio M, Shim H, Mao H, Tucker-Burden C, Silverstein RL, Brat DJ, Olson JJ, Van Meir EG: Vasculostatin inhibits intracranial glioma growth and negatively regulates in vivo angiogenesis through a CD36-dependent mechanism. Cancer Res 2009, 69:1212-1220.
• [40]Maciel GA, Baracat EC, Benda JA, Markham SM, Hensinger K, Chang RJ, Erickson GF: Stockpiling of transitional and classic primary follicles in ovaries of women with polycystic ovary syndrome. J Clin Endocr Metab 2004, 89:5321-5327.
• [41]Abramovich D, Irusta G, Bas D, Cataldi NI, Parborell F, Tesone M: Angiopoietins/TIE2 system and VEGF are involved in ovarian function in a DHEA rat model of polycystic ovary syndrome. Endocrinology 2012, 153:3446-3456.
• [42]Artini PG, Monti M, Matteucci C, Valentino V, Cristello F, Genazzani AR: Vascular endothelial growth factor and basic fibroblast growth factor in polycystic ovary syndrome during controlled ovarian hyperstimulation. Gynecol Endocrinol 2006, 22:465-470.
• [43]Tan BK, Adya R, Chen J, Farhatullah S, Heutling D, Mitchell D, Lehnert H, Randeva HS: Metformin decreases angiogenesis via NF-kappaB and Erk1/2/Erk5 pathways by increasing the antiangiogenic thrombospondin-1. Cardiovasc Res 2009, 83:566-574.
• [44]Fulghesu AM, Cucinelli F, Pavone V, Murgia F, Guido M, Caruso A, Mancuso S, Lanzone A: Changes in luteinizing hormone and insulin secretion in polycystic ovarian syndrome. Hum Reprod 1999, 14:611-617.
• [45]Halpin DM, Charlton HM: Effects of short-term injection of gonadotrophins on ovarian follicle development in hypogonadal (hpg) mice. J Reprod Fertil 1988, 82:393-400.
• [46]McNeilly JR, Watson EA, White YA, Murray AA, Spears N, McNeilly AS: Decreased oocyte DAZL expression in mice results in increased litter size by modulating follicle-stimulating hormone-induced follicular growth. Biol Reprod 2011, 85:584-593.
• [47]Lin P, Rui R: Effects of follicular size and FSH on granulosa cell apoptosis and atresia in porcine antral follicles. Mol Reprod Dev 2010, 77:670-678.
• [48]Wang XL, Wu Y, Tan LB, Tian Z, Liu JH, Zhu DS, Zeng SM: Follicle-stimulating hormone regulates pro-apoptotic protein Bcl-2-interacting mediator of cell death-extra long (BimEL)-induced porcine granulosa cell apoptosis. J Biol Chem 2012, 287:10166-10177.
• [49]Hunzicker-Dunn ME, Lopez-Biladeau B, Law NC, Fiedler SE, Carr DW, Maizels ET: PKA and GAB2 play central roles in the FSH signaling pathway to PI3K and AKT in ovarian granulosa cells. Proc Natl Acad Sci U S A 2012, 109:E2979--2988.
• [50]Zhou D, Samovski D, Okunade AL, Stahl PD, Abumrad NA, Su X: CD36 level and trafficking are determinants of lipolysis in adipocytes. FASEB J 2012, 26:4733-4742.
• [51]Aroda V, Ciaraldi TP, Chang SA, Dahan MH, Chang RJ, Henry RR: Circulating and cellular adiponectin in polycystic ovary syndrome: relationship to glucose tolerance and insulin action. Fertil Steril 2008, 89:1200-1208.
• [52]Glintborg D, Hojlund K, Andersen M, Henriksen JE, Beck-Nielsen H, Handberg A: Soluble CD36 and risk markers of insulin resistance and atherosclerosis are elevated in polycystic ovary syndrome and significantly reduced during pioglitazone treatment. Diabetes Care 2008, 31:328-334.
• [53]Haouzi D, Assou S, Monzo C, Vincens C, Dechaud H, Hamamah S: Altered gene expression profile in cumulus cells of mature MII oocytes from patients with polycystic ovary syndrome. Hum Reprod 2012, 27:3523-3530.
• [54]Kaur S, Archer KJ, Devi MG, Kriplani A, Strauss JF 3rd, Singh R: Differential gene expression in granulosa cells from polycystic ovary syndrome patients with and without insulin resistance: identification of susceptibility gene sets through network analysis. J Clin Endocr Metab 2012, 97:E2016-E2021.
• [55]Schmidt J, Weijdegard B, Mikkelsen AL, Lindenberg S, Nilsson L, Brannstrom M: Differential expression of inflammation-related genes in the ovarian stroma and granulosa cells of PCOS women. Mol Hum Reprod 2013, 20:49-58.